(Reuters) -Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy ...

马萨诸塞州剑桥市 - 在生物制药板块一项重大举措中，市值1,280亿美元、财务状况稳健的制药巨头Bristol Myers Squibb（纽交所股票代码：BMY）已达成最终协议，将以每股5.00美元的全现金交易收购2seventy bio, Inc.

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

CAMBRIDGE, Mass., March 11, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under ...

PRINCETON, N.J. - 欧盟委员会已批准制药巨头Bristol Myers ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

Bio (TSVT) announced a definitive merger agreement under which Bristol Myers Squibb (BMY) will acquire all of the outstanding shares ...

Bristol Myers Squibb is acquiring 2seventy bio, a deal that gives the pharmaceutical giant full control over the partnered cancer cell therapy Abecma as that product faces headwinds in a ...

Bristol Myers (BMY)’ treatment of small cell lung cancer, atigotatug plus nivolumab fixed dose combination, received FDA orphan designation, ...